The decision regarding whether to use a PAb or MAb depends on a number of factors, the most important of which are its intended use and whether the antibody is readily available from commercial suppliers or researchers.
PAbs can be produced more quickly, at lower costs, and with less technical skill than is required to produce MAbs. You can also navigate www.bosterbio.com/services/custom-antibody-production-services to get antibody production services.
PAbs can be expected to be obtained within months of immunization initiation, whereas hybridoma generation and subsequent MAbs production can, in some cases, take up to a year or more, and therefore require significantly more time and cost. . The "finished" reagent avoids the problem of time and often cost.
Image Source: Google
The main advantage of MAbs is their homogeneity and consistency. The monospecificity provided by MAbs is useful for assessing changes in molecular conformation, protein-protein interactions, and phosphorylation status, as well as for identifying individual members of protein families.
It also allows the potential for structural analysis (eg X-ray crystallography or gene sequencing) of antibodies to be determined at the molecular level. However, the monospecificity of MAbs may also limit their usefulness.
Minor changes in epitope structure (eg as a result of genetic polymorphism, glycosylation, and denaturation) can significantly affect MAb function.
For this reason, MAbs must be generated in the antigenic state to which they will eventually bind. In contrast, because PAbs are heterogeneous and recognize multiple antigenic epitopes, the effect of alteration on one or a small number of epitopes is less likely.